S. Schreiber

发表

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

D. Schwartz, W. Sandborn, G. Lichtenstein, 2014, Alimentary pharmacology & therapeutics.

Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study

Tariq Ahmad, Judy H Cho, Vibeke Andersen, 2016, The Lancet.

Decreased interleukin-1 receptor antagonist response following moderate exercise in patients with colorectal carcinoma after primary treatment.

H. Allgayer, S. Schreiber, Susanne Nicolaus, 2004, Cancer detection and prevention.

Gordonibacter pamelaeae gen. nov., sp. nov., a new member of the Coriobacteriaceae isolated from a patient with Crohn's disease, and reclassification of Eggerthella hongkongensis Lau et al. 2006 as Paraeggerthella hongkongensis gen. nov., comb. nov.

K. Timmis, R. Pukall, B. Tindall, 2009, International journal of systematic and evolutionary microbiology.

Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis.

E. Steinhagen-Thiessen, J. Mössner, R. Löfberg, 2005, World journal of gastroenterology.

Allelic variation of the matrix metalloproteinase‐9 gene is associated with collagenous colitis

M. Stolte, S. Miehlke, S. Schreiber, 2011, Inflammatory bowel diseases.

NOD2/CARD15 gene polymorphisms are not associated with collagenous colitis

M. Stolte, S. Miehlke, S. Schreiber, 2007, International Journal of Colorectal Disease.

Four‐week open‐label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis

M. Kamm, I. Talbot, P. Gionchetti, 2002, Alimentary pharmacology & therapeutics.

Safety and tolerability of antagonist anti‐human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease

P. Rutgeerts, L. Boon, J. Ceuppens, 2005, Alimentary pharmacology & therapeutics.

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

M. Kamm, I. Talbot, P. Gionchetti, 2003, Gut.

Base-pair resolution DNA methylome of the EBV-positive Endemic Burkitt lymphoma cell line DAUDI determined by SOLiD bisulfite-sequencing

R. Siebert, J. Richter, P. Rosenstiel, 2013, Leukemia.

The IBD International Genetics Consortium Provides Further Evidence for Linkage to IBD4 and Shows Gene‐Environment Interaction

Judy H. Cho, M. Silverberg, R. Duerr, 2005, Inflammatory bowel diseases.

Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐β‐1a in moderately active ulcerative colitis

M. Shieh, J. Panés, H. Graffner, 2008, Alimentary pharmacology & therapeutics.

Maintenance infliximab (Remicade) is safe, effective and steroid-sparing in Crohn's disease: Preliminary results from the accent i trial

P. Rutgeerts, S. Hanauer, D. Wolf, 2001 .

Genetic Analysis in A Dutch Study Sample Identifies More Ulcerative Colitis Susceptibility Loci and Shows Their Additive Role in Disease Risk

Cleo C. van Diemen, C. Wijmenga, H. Boezen, 2010, The American Journal of Gastroenterology.

A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn’s disease (ENACT-2)

P. Rutgeerts, S. Hanauer, I. Lawrance, 2004 .

Classic IL-6R signalling is dispensable for intestinal epithelial proliferation and repair

P. Rosenstiel, J. Scheller, S. Rose-John, 2016, Oncogenesis.

INFLAMMATORY BOWEL DISEASE Genetic Analysis in A Dutch Study Sample Identifi es More Ulcerative Colitis Susceptibility Loci and Shows Their Additive Role in Disease Risk

C. Wijmenga, D. Hommes, A. Franke, 2010 .

Allelic variation of the matrix metalloproteinase‐9 gene is associated with collagenous colitis

M. Stolte, S. Miehlke, S. Schreiber, 2011, Inflammatory bowel diseases.